Document Type : Original Article
Authors
1 Department of Pharmacology and Therapeutics, University of Nigeria, Enugu Campus, Enugu Nigeria
2 Nsukka District Hospital, Nsukka, Enugu State, Nigeria
3 Department of Science Laboratory Technology, University of Nigeria, Nsukka, Enugu State, Nigeria
Abstract
Background: This study evaluated the gender-dependent potency and side effects of Highly Active Antiretroviral Therapy regimens (i) Zidovndine/Lamuvidine/ Nevirapine (ii) Tenofovir/Emtricitabine/Effavirenz on HIV-positive/AIDs patients attending Nsukka district hospital Enugu, from January 2013 to December 2013.
Method: A retrospective study of two hundred (200) patients of both sexes within the age bracket of 15 – 70 years attending Nsukka District hospital who were treated with HAART was conducted. Clinical and laboratory data were obtained through self developed validated data collection form.
Results: Abdominal pains and diarrhea (3.3%) were the most reported clinical manifestations in regimen 1, followed by headache and chills (2.2%) while in regimen 2, headache, hotness and dizziness (2.4%) were the most reported clinical manifestations followed by pruritis. HAART 1 showed more adverse effects than HAART 2 on both sexes on most of the biochemical variables; glucose (34.57±95.97 - 4.89±0.3 mmol/l), cholesterol (17.33±39.87 - 3.63±0.62 mmol/l), serum glucotransaminase (SGOT) (36.78±27.76 - 32.83±17.10 iu/l), blood urea nitrogen (BUN), (18.66±13.33 - 15.14±6.01mg/dl) and amylase (126.29±186.21 - 104.43±31.38 µg/l).While both regimens showed improved immunological and hematological outcomes: CD4+; 282.03±219.57 - 380.89±241.21 cells/µl (HAART1), 312.09±242.60-404.15±253.17 cells/µl (HAART2), hemoglobin(Hb) 10.60±1.74 - 10.93±1.81 g/dl (HAART1), 10.46 ±2.00 - 11.46±1.85 g/dl (HAART2).
Conclusion: The adverse effects on clinical manifestation were more noticeable in regimen 1 in the study population, with the female population being the greater affected. Comparison of the two regimens with respect to their adverse effects on clinical manifestation favors regimen 2.
Keywords
Main Subjects
- Adeyi PJ, Kanki O, Odutolu JA. Idoko (Eds.), AIDS in Nigeria: A Nation on the Threshold, Harvard Center for Population and Development Studies, Cambridge (Massachusetts). 2006.
- Patil R, Ona MA, Papafragkakis H, Carey J, Moshenyat Y, Alhaddad A, et al. Acute Liver Toxicity due to Efavirenz/Emtricitabine/ Tenofovir. Case Reports in Hepatology. 2015; 2015:1–2.
- Makinde K, Okusanya BO, Akinajo OR. Maternal side effects of efavirenz‐containing highly active antiretroviral therapy (HAART): A comparative study of HIV‐positive pregnant and nonpregnant women in a tertiary hospital. Trop J Obstet Gynaecol 2019; 36:218‐
- Xi, P. XuGlobal colorectal cancer burden in 2020 and projections to 2040 Transl. Oncol. 2021; 14 (10), Article 101174, 10.1016/J.TRANON.2021.101174.
- Rakshith HT, Lohita S, Anvil Preem Rebello, Prakash S, Goudanavar N, Raghavendra N. Sex differences in drug effects and/or toxicity in oncology. Curr Res Pharmacol Drug Discov, 2023; 4: 100152.
- Konstandi, M. Psychophysiological stress: a significant parameter in drug pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 2013; 9: 1317–34. doi: 10.1517/17425255.2013.816283
- Konstandi M, Johnson E O, Lang M A. Consequences of psychophysiological stress on cytochrome P450-catalyzed drug metabolism. Neurosci. Biobehav. Rev. 2014; 45: 149–67. doi: 10.1016/j.neubiorev.2014.05.011
- Konstandi M, Johnson EO, Lang Stress as a Potential Regulatory Factor in the Outcome of Pharmacotherapy. Front. Neurosci, 2022; 16:737716.
- Khan R, Bilal A, Siddiqui SH. Knowledge About HIV and Discriminatory Attitudes Towards People Living with HIV in Pakistan, USAID, DHS Working Paper No. 134. 2017.
- Vidya Vijayan KK, Karthigeyan KP, Tripathi SP, Hanna LE. Pathophysiology of CD4+ T-Cell Depletion in HIV-1 and HIV-2 Infections. Front Immunol. 2017; 8:580. doi: 10.3389/fimmu.2017.00580. PMID: 28588579; PMCID: PMC5440548.
- Mabayoje O, Muhibi M, Mustapha A, Fadiora O, Taiwo Adewole. The Effect of Highly Active Antiretroviral Therapy on CD4 Counts and Body Weight in HIV/AIDS Patients in South West Nigeria. Research Journal of Medical Sciences, 2012; 6: 228-31.
- International antiviral society–USA Panel. Recommendation on antiretroviral treatment of adult HIV infection: JAMA 308 (4). doi:1001/jama. 2012.796
- Mandell GL, Bennett JE, Dolin R. Antiretroviral Therapy for Human Immunodeficiency Virus Infection. Principles and Practice of Infectious Diseases, 7th Edition. Churchill Livingstone. 2009. ISBN 978-0-443-06839-3.
- Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 2012; 2012.
- Mansour-Ghanaei R, Mansour-Ghanaei F, Naghipour M, Joukar F. Biochemical markers and lipid profile in nonalcoholic fatty liver disease patients in the PERSIAN Guilan cohort study (PGCS), Iran. J Fam Med Prim Care 2019; 8(3):923.
- Bera E, Naidoo D, Williams M. Maternal deaths following nevirapine-based antiretroviral therapy. Southern African Journal of HIV Medicine. 2012; 13(4):196–7.
- Widiyanti M, Adiningsih S, Natalia EI, Purba DA. Effect of antiretroviral therapy to liver function of people living with HIV/AIDS patients in West Papua. Indonesian Journal of Medicine and Health, 2021; 12(2):116-23.
- Yimam G, Tadesse L, Tigist G, Siti Qamariyah K, Dominicus H, Kuntaman K, Maria Inge L. HAART induced inflammation, toxicity and its determinants among HIV positive children in Addis Ababa, Ethiopia. Heliyon, 2023; 9 (5): e15779.
- Raghu R, Jesudas B, Bhavani G, Ezhilarasan D, Karthikeyan S. Silibinin mitigates zidovudine-induced hepatocellular degenerative changes, oxidative stress and hyperlipidaemia in rats. Human and Experimental Toxicology. 2015; 34(11):1031–42.
- Akpan EJ, Akpan UE, Etim OE, Bassey UE. Effect of first and second line fixed-dose combination (FDC) antiretroviral drugs on hepatic enzymes, serum protein and liver histology of albino Wistar rats. IOSR Journal of Biotechnology and Biochemistry. 2019; 5(6):54–61.
- Lucien1 KFH, Clement ANJ, Fon NP, Weledji P. Ndikvu CP. The effects of antiretroviral treatment on liver functionEnzymes among hiv-infected out patients attending the central Hospital of yaounde, Cameroon. Afr. J. Cln. Exper. Microbiol 2010; 11(3): 174-78.
- Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev. 2003; 5:36–43.
- Tesfa E, Siefu D, Belayneh Y, Mekonnen Liver enzyme elevation in patients taking HAART compared with treatment naïve controls at Debre Berhan Referral Hospital: a comparative cross-sectional study, Northeast Ethiopia. BMC Res Notes 2019; 12(1): 714. https://doi.org/10.1186/s13104-019-4748-4.
)